TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics

TRACON Pharmaceuticals, Inc. (TCON): $0.18

0.01 (+3.37%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add TCON to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#165 of 382

in industry

TCON Price/Volume Stats

Current price $0.18 52-week high $2.19
Prev. close $0.18 52-week low $0.17
Day low $0.18 Volume 2,504
Day high $0.18 Avg. volume 286,475
50-day MA $0.26 Dividend yield N/A
200-day MA $0.96 Market Cap 5.65M

TCON Stock Price Chart Interactive Chart >


TRACON Pharmaceuticals, Inc. (TCON) Company Bio


Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.


TCON Latest News Stream


Event/Time News Detail
Loading, please wait...

TCON Latest Social Stream


Loading social stream, please wait...

View Full TCON Social Stream

Latest TCON News From Around the Web

Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

Full ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses o

Yahoo | September 18, 2023

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overvi

Yahoo | September 5, 2023

7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole

There are some solid biotech stocks on the market.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | August 25, 2023

Q2 2023 TRACON Pharmaceuticals Inc Earnings Call

Q2 2023 TRACON Pharmaceuticals Inc Earnings Call

Yahoo | August 15, 2023

TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time

Yahoo | August 14, 2023

Read More 'TCON' Stories Here

TCON Price Returns

1-mo -31.30%
3-mo N/A
6-mo -90.72%
1-year -89.22%
3-year -96.13%
5-year -99.12%
YTD -87.92%
2022 -46.21%
2021 -76.32%
2020 400.00%
2019 -62.86%
2018 -81.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!